Shares of OncoSec Medical Inc. (OTC: ONCS), a biopharmaceutical company engaged in the development of advanced-stage OMS ElectroOncology therapies to treat solid tumor cancers and metastatic disease, are climbing in trading today.
At last check, ONCS shares were trading 5.53% higher at $0.248 on volume of 1.37 million.
ONCS shares are gaining today after the company announced data from an interim analysis of two randomized Phase 3 clinical trials, HNBE-01 and HNBE-02, using electrochemotherapy to treat locally recurrent and second squamous cell carcinoma of the head and neck.
Punit Dhillon, President and CEO of OncoSec Medical, said that interim analysis of the two Phase 3 studies and the recently released data from the Phase 4 study carried out in Europe, has shown that the primary endpoint of maintain quality of life was achieved.
Recent Comments